Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia-Reference-Cited by-同舟云学术

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Published:2015-10-22 Issue:3 Volume:172 Page:392-400
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Ravandi Farhad¹,Jorgensen Jeffrey L.²,O'Brien Susan M.¹,Jabbour Elias¹,Thomas Deborah A.¹,Borthakur Gautam¹,Garris Rebecca¹,Huang Xuelin³,Garcia-Manero Guillermo¹,Burger Jan A.¹,Ferrajoli Alessandra¹,Wierda William¹,Kadia Tapan¹,Jain Nitin¹,Wang Sa A.²,Konoplev Sergei²,Kebriaei Partow⁴,Champlin Richard E.⁴,McCue Deborah⁵,Estrov Zeev¹,Cortes Jorge E.¹,Kantarjian Hagop M.¹

Affiliation:

1. Departments of Leukemia; The University of Texas MD Anderson Cancer Center; Houston TX USA

2. Departments of Hematopathology; The University of Texas MD Anderson Cancer Center; Houston TX USA

3. Departments of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston TX USA

4. Departments of Stem Cell Transplantation and Cellular Therapy; The University of Texas MD Anderson Cancer Center; Houston TX USA

5. Departments of Pharmacy; The University of Texas MD Anderson Cancer Center; Houston TX USA

Funder

University of Texas MD Anderson Cancer Center

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13834/fullpdf

Reference36 articles.

1. Molecular genetics of acute lymphoblastic leukemia;Armstrong;Journal of Clinical Oncology,2005

2. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia;Bar;Leukemia Research and Treatment,2014

3. Modern therapy of acute lymphoblastic leukemia;Bassan;Journal of Clinical Oncology,2011

4. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL);Bassan;Blood,2009

5. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia;Beldjord;Blood,2014

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia;Annals of Hematology;2024-03-18

2. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia;Blood Advances;2024-02-15

3. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-12

4. HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B‐cell acute lymphoblastic leukemia;European Journal of Haematology;2023-11-06

5. Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia;European Journal of Haematology;2023-09-05